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Abstract Exhaled nitric oxide (eNO) is elevated in patientswith asthma in contrastto healthy subjects, althoughthe
variabilityishigh.Inthis study, wetried to reducethevariabilityof eNOinhealthy subjects.Wemeasured eNOusing ERS
guidelines with a fixed exhalation flow of 250ml/s in117 (72 women,45 men) non-smoking healthy subjects and corre-
latedthis to antropometricdata and standardlung functionmeasurements.Usingamodelpreviouslydefinedby Hyde et
al., we selectedparameters thatwere likely to have ahigh correlationwith eNO.ENOwaslog-normallydistributed.The
normalvalues foreNOare significantly (Po0.001) differentformenandwomen: inwomenmeanln eNOlevels (SD) were
1.49 (0.34), inmen1.74 (0.41) (back-transformedvalue 4.43 resp. 5.73 ppb).Usingmultipleregression analysis, onlylnDm,CO,
lnTLC and ln sGaw showed a significant positive correlationwith ln eNO inmen, although only 20% of the variability of
eNO could be explained. Inwomen no correlationwas observed and only 5% of the variability was explained.The high
variability of eNO could only partly be explained inmen, whichmakes the use of reference equations not very helpful.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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In the past years many studies were conducted to unra-
vel the role and origin of nitric oxide (NO) in pulmonary
diseases (1). NO is produced by NO-synthase (NOS), of
which three isoforms has been identi¢ed (2).Two of the
isoforms are located in the bronchial epithelium, namely
neuronal NOS (nNOS) and inducible NOS (iNOS). In the
pulmonary vascular system endothelial NOS (eNOS) is
expressed in the endothelium, where it produces NO,
which acts as a vasodilator. As an increase in exhaled
NO (eNO) is seen in asthmatics subjects (3), the re-
search has been focussed on the airway epithelium. In
transbronchialbiopsies, a great increase in iNOS-expres-
sion has been seen in asthmatic subjects, induced by
proin£ammatory cytokines (2). Furthermore, the ex-
pression of iNOS correlates with the activity of the dis-
ease (4^6), leading to the hope that eNO couldbe a new
measurement tool for disease activity in asthmatic pa-
tients. In all studies concerning eNO in healthy and asth-
matics subjects, a substantial overlap between the twoReceived 29 April 2002, accepted 29 April 2002.
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power of the eNOmeasurement.Therefore, it is impor-
tant to try to explain the variability of eNO in detail, in
order to increase the discriminative power of the mea-
surement.Hyde et al. (7) proposed a modelwhich incor-
porates the production of NO by the lungs (VNO), the
di¡using capacity for NO (DNO) that carries NO into
the pulmonary capillary blood and the removal by exha-
lation (VA).Hyde derivedrelevant equations andwas able
to predict steady-state NO levels in subjects.
PL ¼ VNODNO þ VA= PB  PH2OÞ:ð
The above equation shows the relationship between
exhaled NO levels (PL), NO di¡usion (DNO), production
(VNO) and removal by exhalation (VA). PB depicts atmo-
spheric pressure, while PH2O is the saturated water
vapor pressure (47mmHg or 6.3kPa). (Derived from
Hyde et al. (7)).
In this study, we measured exhaled NO levels in
healthy subjects to determine the ‘normal’ levels and at-
tempt to reduce the variability by correcting for covari-
ates, whichwere derived from the‘Hyde-model’.
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Model development
Based on the model from Hyde we determined para-
meters that in£uence eNO levels. The ¢rst parameter
is the NO di¡usion capacity (DNO). Since there is no
measuringmethod available for this parameter, we used
the membrane conductance for carbon monoxide
(Dm,CO) (8) because it is closely related to DNO. DNO
re£ects the membrane conductance like Dm,CO and
Borland (9) showed that DCO and DNO are related to
each other by a factor 4.3.
The production of NO depends on the NOS activity
levels, which cannot be measured non-invasively. How-
ever,NOS catalysis the conversion of L-arginine into L-ci-
trulline thereby producing NO. As the levels of eNO are
in£uenced by the intrapulmonary (10) or intravenously
(11) administered L-arginine, serum L-arginine levels could
a¡ect eNO.
The ERS criteria (12) for NO measurements request
the use of a ¢xed exhalation £ow.This results in a depen-
dency of eNO on TLC: in larger lungs the balance be-
tween adding and removing NO shifts. Based on this
approach we incorporated total lung capacity in our
model. A similar line of reasoning leads to the measure-
ment of the physiological dead space volume (VD), which
can act as a storage barrel for NO. Next to these mea-
surements, standard lung function parameters were
measured: peak£ow, MEF75/50/25, (forced) vital capacity,
FEV1, and sGaw.
Subjects
Included were healthy volunteers, not on medication,
non- or ex-smokers (quitted more than six months).
The exclusion criteria consisted of respiratory tract in-
fection (including rhinitis) in the past 6 weeks, atopic dis-
orders, e.g. seasonal rhinitis, hay fever, eczema andother
allergies.
Lung function
Whole body plethysmography was performed on 6200
Autobox DL (SensorMedics Cooperation, Yorba Linda,
CA,U.S.A.)with the determination of static anddynamic
lung volumes and airway resistance (Raw).
Carbonmonoxide di¡usion capacity, including its sub-
divisions Dm,CO and Qc, was measured on a MasterLab
Pro (Erich Jaeger GmbH, Wurzburg, Germany). Dm,CO
and Qc were determined with the single-breath maneu-
ver technique according to Cotes (13). Physiological dead
space (Vd) measurement was done on an Oxycon Alpha
(Erich Jaeger GmbH,Wurzburg, Germany), volume and
CO2 calibrations were performed daily. During tidal
breathing CO2 was continuously measured via a sidearm.Vdwas calculatedusing the Bohr equation. Inhealthy
subjects the di¡erence between PaCO2 and PetCO2 is
negligible, sowe used PetCO2.
Nitric oxidemeasurements
NOmeasurementswereperformedon a chemolumines-
cence analyzer (type CLD 77 AM, Eco Physics, Zurich,
Switzerland). System speci¢cations are detection limit
0.02^0.05ppb, reaction time 0.1s, and continuous on-line
measurement of NO. Sampling £ow was kept constant
at 325ml/min. Expiratory £ow was measured by means
of molecular mass gas analysis with ultrasonic transdu-
cers,CO2wasmeasuredvia a side armby infrared sensor
(Spiroson Scienti¢c unit, Isler Bioengineering, Dˇrnten,
Switzerland).
eNOmeasurements were performed in all subjects in
the morning after an overnight fast, before other tests.
After the inhalation of NO-free air toTLC, the subjects
exhaled against a positive pressure of 5 cm H2O, thus
preventing nasal air leakage. Expiratory £ow was kept
constant according to ERS recommendations (12) by
means of a feedback systemwith a visual scale represent-
ing the on-linemouth pressure, leading to a constant ex-
piratory £owof 250ml/s.Each subject repeated the slow
exhalation for at least 5 times, with reproducible curves.
In all subjects end-tidal NO plateau phase was taken as
the eNO value. Before each measurement a zero-point
calibration was performed.Twice weekly the NO analy-
zer was calibrated using zero-NO air, made by room air
whichwas led through anNO capturing ¢lter, andNOin
N2 50ppm (Linde Ag,Unterschleiheim,Germany).
Blood samples were taken from all subjects in the
morning after an overnight fast.Quantitative analysis of
arginine was performed on a Biochrom 20 amino acid
analyzer with an ion-exchange column (Amersham Phar-
macia Biotech,Cambridge,U.K.).
Statistics
Exhaled NO levels are lognormal distributed as de-
scribed earlier (14^16): a Kolmogorov^Smirnov test
showed a signi¢cantdeparture from the normal distribu-
tion (Po0.001). In consequence, all calculations were car-
ried outwith the ln-transformedvalues.The necessity to
ln-transformwas also present with the other measured
(lung function) parameters. Jilma et al. (17) reported that
eNO levels are higher in men than in women, therefore
we compared levels inmen andwomen by an unpaired t-
test.
The parameters listed above and the eNO levels were
incorporated into a multiple regression model. Incor-
poration of a multitude of (irrelevant) parameters can
weaken the predictive power of any multiple regression
model: we de¢neduseful parameters as thosewho show
1016 RESPIRATORYMEDICINEhigh correlation with eNO levels, but with low intercor-
relations (18,19).To de¢ne the multiple regression model
weused forward selection of parameters. Analyseswere
carried outusing SPSS10 (SPSS Inc.,Chicago,U.S.A.).The
anthropometric data are depicted asmean and standard
deviations (SD), a-levels were 0.05.The lung function was
expressed as the mean (SD) of the number of standard
deviations of the predicted value.
RESULTS
Of123 subjects who volunteered in this study 6 subjects
were excluded as they did not perform all pulmonary
function tests, leaving 117 eligible persons, 72 women
and 45 men. The women’s age was 38.3711.5 (range 17^
61), male age was 40.1710.8 (range 25^64). The weight
(in the same order) 66.078.8 and 82.6711.8kg, body
mass index, respectively, 23.173.1 and 24.772.9kg/m2,
height 1.6970.06m, respectively, 1.8370.07m. The lung
function of all subjects was shown to be within normal
limits (20). The FEV1 in women and men was, respec-
tively, 0.6171.1 and 0.5970.59 standard deviations o¡
predicted, theTLC 0.9371.11 and 0.8871.15, the residual
volume 0.3871.08 and 0.3571.13.The CO-transfer values
again expressed as standard deviations o¡ predicted for
women showed a small but signi¢cant departure from
zero: 0.8 SDs (95% CI: 1.1 to 0.5). This indicates a
somewhat lower CO-transfer value than expected. For
men no signi¢cant departure was found: 9.75102 SDs
o¡ predicted (95% CI:0.44 to 0.24).TABLE 1. Descriptive summaryof eNOlevels inhealthymen an
ln-transformed eN
Women Mean 1.49
Lower^upper 95% CI 1.41^
7 2 SDrange 0.69^
Men Mean 1.74
Lower^upper 95% CI 1.62^
7 2 SDrange 0.93^
The 95% con¢dence intervals depictthe interval ofthemean f
TABLE 2. Correlations between the ln-transformed values o
volunteers
Dm,CO VD sGaw
Correlation coe⁄cient 0.113 0.174 0.105
P-value 0.225 0.062 0.259
Signi¢cantcorrelations are printed in bold.Themean eNO-levels, the 95%CI of themean and the
72 SD range are depicted inTable 1. The unpaired t-test
showed highly signi¢cant (Po0.001) di¡erences in eNO
levels between men and women. Mean ln-transformed
eNO levels were 1.49 (0.34) in women and 1.74 (0.41)
lnppb in men, which corresponds to geometric means
of, respectively, 4.43 and 5.73ppb (Table1): further calcu-
lationswere done inmen andwomen separately.The cor-
relation matrix between the eNO levels and the others
parameters revealed that TLC and weight were signi¢-
cantly correlatedwith eNO (Table 2).The signi¢cant cor-
relation between eNO and weight is however an
arti¢cial one because in a correlation matrix for women
andmen separately, the weight^ eNO correlation disap-
peared: inwomen the correlation coe⁄cientdropped to
0.049 (P=0.685) and inmen to 0.279 (P=0.064).
Within themale and female groups no correlationwas
present between eNO levels and age (P40.05). When
the parameters fromTable 2 were used in a multiple re-
gression analysis none of the parameters could act as
powerful predictor of eNO levels in women (Table 3).
Only 5.2% of the variance present in women was ex-
plained by the regression analysis.The residual standard
deviation in this case was 0.352. In men, 20% of the var-
iance was explained, while the regression analysis
showed signi¢cance (P=0.034).The residual standard de-
viationwas 0.366.
Considering the large number of irrelevant para-
meters, but also knowing the signi¢cant correlation be-
tweenTLC and eNO levels, we simpli¢ed the model to
one containing Dm, sGaw and TLC. The outcome shows
that the regression becomes stronger in male (P=0.008)dwomen







or the ln-transformed eNOvalues.
f eNO levels and explored parameters in the entire group
TLC Weight Qc Arginine levels
0.200 0.284 0.150 0.690
0.030 0.002 0.107 0.458
TABLE 3. Regression coe⁄cients of themultiple regression analysis between eNOlevels andparameters shown
Men Women
Regression coe⁄cient P-value Regression coe⁄cient P-value
Dm,CO 1.000 0.026 0.258 0.400
Vd 0.138 0.635 0.149 0.397
sGaw 0.543 0.010 0.121 0.428
TLC 1.158 0.100 0.359 0.375
Weight 0.590 0.208 0.188 0.569
Qc 0.024 0.958 0.147 0.638
Arginine levels 0.0054 0.103 0.00091 0.709
Constant 0.525 0.814 1.511 0.348
The coe⁄cients re£ectthe outcome after ln-transformation ofthe data.
TABLE 4. Regression coe⁄cients ofthe reduced‘male’and‘female’multiple regression analysis between eNOlevels and para-
meters shown
Men Women
Regression coe⁄cient P-value Regression coe⁄cient P-value
Dm,CO 0.874 0.016 0.169 0.509
sGaw 0.572 0.005 0.106 0.464
TLC 1.408 0.100 0.187 0.589
Constant 1.065 0.342 2.196 0.003
The coe⁄cients re£ectthe outcome after ln-transformation ofthe data.
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females still no signi¢cant regressionwas found.
Regression coe⁄cients for Dm,CO, TLC and sGaw in
women and men showed were strongly di¡erent in
either magnitude or sign. Subsequently, we tried to ex-
plain sexdi¡erences in eNOlevelsby incorporating these
parameters in a co-variance analysis, which included the
parameters mentioned and the interaction between sex
and these parameters. The results indicate that the sex
di¡erence in eNO levels became non-signi¢cant
(P=0.384). The strongest factors were Dm,CO (P=0.016),
sGaw (P=0.005) and the interaction between TLC and
sex (P=0.01). The other factors or interactions were
barely not or not signi¢cant. The signi¢cant interaction
between sex and TLC is visualized in Fig.1: it shows a po-
sitive correlation between TLC and eNO levels in men
and a negative one inwomen.
DISCUSSION
The reduction of variability of eNO levels by using co-
variates derived from the Hyde-model (7) appeared to
be small. A key factor in this model is the cellular NO
production, which is not present in our approach be-cause it can only be measured by means of invasive pro-
cedures. When a reliable (and easy) method for the
measurement of cellular NO production becomes avail-
able we probably can explain more of the eNO level
variability.Therefore, we cannot reject or accept the va-
lidity of the Hyde-model in explaining eNO levels. In our
study serum L-arginine levels were not correlated to
eNO levels and will not be a measure for cellular NO
production.
Recently, another model for exhaled NO levels was
published by Silko¡ et al. (21).This model is based on the
assumption that the alveoli produce NO, leading to a
concentrationCalv.On expiration the conducting airways
add NO to the alveolar amount.The amount added de-
pends on the NO-concentration in the airway wall (Cw),
the transfer of NO from themucosa to the air (DNO) and
the expiratory air£ow.When the £ow is high, not much
NO-molecules canbe added to avolume of air due to the
short contact time. At in¢nite £ows the eNOconcentra-
tion therefore equals the alveolar concentration. The
Silko¡model o¡ers no newways to reducevariability be-
cause the parameters in that model (Cw, Calv and DNO)
are derived by non-linear regression from eNO-levels.
















FIG. 1. Scatterplotof eNOlevels and TLC (both ln-transformed) showing that inmen a largerTLCmeans higher eNOlevels and the
opposite phenomenon inwomen.The lines showndepictthe regression in both groups.
1018 RESPIRATORYMEDICINEIn our study £ows of approximately 250ml/s were
used, what according to Silko¡ et al. would not re£ect
bronchial NO-production, but foremost alveolar NO. In
this sense, we like to point at many studies which de-
tected high eNO-levels in asthma (being a disease of the
bronchi) using 250ml/s expiratory £ow (22,23).
Reference equations derived from our measurements
will have a low predictive power.This implies that large
di¡erences are needed to discriminate between normal
and abnormal values.Only if the changes in eNOinduced
by disease are substantial, thewide range of ‘normal’ va-
lues will not overlapwith the values in diseased subjects.
Simpson and co-workers (24) measured in steroid nave
asthmatics mean eNO levels (exhalation £ow rate
100ml/s) of 9.09 or 17.69ppb depending whether or not
the patients recently had been exposed to indoor aller-
gens, which probably means a considerable overlap be-
tween healthy volunteers and asthmatics. It can be
calculated that, assuming an overlap ofr5% between dis-
eased and healthy eNO-values and based on ourmeasure-
ments, eNO levels in female asthmatics should show a
mean (SD) of 2.84 (0.34) and in male asthmatics of 3.34
(0.41) lnppb to discriminate clearly between healthy and
asthmatics (back-transformedvalue17.0ppbresp., 28.3ppb).
Increasing the sample size (assuming that sampling
was done in an unbiased way) would not lead to a stron-
ger reduction of eNO levels variability because the stan-
dard deviation of a sample is not dependent on its size.
The only possible conclusion is that the population stan-
dard deviation of eNO levels is relatively large. Com-
pared to other studies in children (15) the range from
the +2 SD to the 2 SD value is similar or even smaller.Baraldi (15) reports such a 4 SD range of 14.5ppb, while
in this study we report 6.65ppb for women and10.3ppb
for men. In young adults, this range is reported to be
19.6 ppb (14). Kharitonov (25), pooling men and women,
reported a 4 SD range of approx. 8.8ppb, which is very
similar to this study.The mean (back-transformed) eNO
levels in this study are lower than that of Kharitonov,
perhaps due to the fact that apparently Kharitonov did
not take account of the lognormal distribution. When
one calculates the straightforwardmean of such a distri-
bution, themean is overestimated.
Jilma (17) reported higher eNO levels in men than in
women (we con¢rm this observation) and concluded
that part of the di¡erences was attributed to body
weight. We disagree with this opinion because when
weight is a signi¢cant factor, this must be so in males
and females, which is not the case.Other factors are re-
sponsible for the sexdi¡erence, namelyTLC,Dm,CO, sGaw
and the interaction between sex and TLC.The fact that
only these factors are to a great extent responsible for
the sex di¡erence rules out major sex di¡erences in the
NO synthase levels and/or activity. If a sex di¡erence in
the latter would exist, we would not be able to explain
the di¡erences using the factors described above.For ar-
guments sake we have to recognize the possibility that
NOS activity in men is lower than in women, this would
lead to a decrease in sex di¡erences in eNO levels, ex-
plained by a reduction of the di¡erences induced byTLC,
Dm,CO, sGaw .This seems unlikely to us becausewhenwe
remove the in£uence of TLC, Dm,CO and sGaw a di¡er-
ence would remain. The remaining di¡erence would be
opposite in sign compared to that reported here.
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sexes: the higher the Dm,CO is, the lower the eNO levels
are. The explanation for this could be quite straightfor-
ward:whenmoreNOdi¡uses into thebloodstream, less
is available for exhalation. The interaction between sex
and Dm,CO was non-signi¢cant, sowe have no arguments
that the e¡ect ofDm,CO is di¡erent inmen andwomen. A
puzzling e¡ect can be noted for theTLC: inmen a larger
TLC means higher NO levels, but in women lowerTLCs
are equivalent to higher levels. This phenomenon ex-
plains the signi¢cant sex byTLC interaction. In men one
could argue that in subjectswith a largeTLC the conduct-
ing airways are relatively larger, leading to a longer con-
tact time between expired air and bronchial epithelium
(with the same £ow rate measured at the mouth). The
opposite character in women rules out such an explana-
tion. It is di⁄cult to ¢nd an explanation for these phe-
nomena, but we can rule out several factors. Men and
women of all build, height, etc., entered this study in a
complete random fashion, so systematic di¡erences due
to instrument bias is very unlikely. The correlation we
found could be false, which is possible when a few out-
liers heavily in£uence the regression line or equation.
We think that this is not the case: ¢rstof all, the variance
in male and female values did not di¡er signi¢cantly as
judgedby the Levene’s test for equality of variances. Sec-
ondly, we did check for the presence of strong in£uen-
cing points in the regression analysis and this check
revealed that no datapoints were present which could
‘tilt’ the regression line in such a way that theTLC-e¡ect
in males is falsely generated.
A correlation between eNO and Vd could not be es-
tablished.The fact that in these healthy subjectNO-pro-
duction in the conducting airwayswill be low will explain
this ¢nding. Moreover, the spread in the Vd-values was
small, thus o¡ering few possibilities to explain eNO-
variability.
In summary, we determined exhaled NO levels in a
group of healthy subjects and only found a weak reduc-
tion of the variability of these levels, using parameters
derived from the model of Hyde or Silko¡. Due to the
low variability reduction, the use of reference equations
is not very helpful. Men show higher eNO levels than
women, which could be explained by the di¡erences in
TLC,Dm,CO and sGaw and not by weight.
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